Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
251,80 € ↑6,70 (2,73%)
2026-06-03
AKTIENPREIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionUBS Group AG
Latest Disclosed Ownership458,870 shares
Latest Disclosed Value $ 151,826,317
UBS Group AG ownership in DUL / Alnylam Pharmaceuticals, Inc.

On May 5, 2026 - UBS Group AG filed a 13F-HR form disclosing ownership of 458,870 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $131,099,159 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 29, 2026 disclosing 825,840 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of -44.44% during the quarter. The current value of the position is $115,543,466 USD.

UBS Group AG has a history of taking positions in derivatives of the underlying security (DUL) in the form of stock options. The firm currently holds call options representing 2,988 of underlying shares valued at $988,640 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

DE:DUL / Alnylam Pharmaceuticals, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-05 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 458,870 -366,970 -44.44 151,826 -53.77 0.0043
2026-01-29 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 825,840 337,636 69.16 328,395 47.51 0.0533
2025-11-13 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 488,204 -55,282 -10.17 222,621 25.61 0.0349
2025-08-14 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 543,486 264,848 95.05 177,225 135.56 0.0307
2025-05-13 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 278,638 -11,328 -3.91 75,238 10.27 0.0138
2025-02-14 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 289,966 134,295 86.27 68,232 59.37 0.0126
2024-11-14 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 155,671 -912 -0.58 42,814 12.52 0.0093
2024-08-14 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 156,583 32,120 25.81 38,050 104.56 0.0094
2024-05-13 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 124,463 33,990 37.57 18,601 7.41 0.0046
2024-02-09 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 90,473 20,571 29.43 17,317 39.89 0.0052
2023-11-09 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 69,902 -3,641 -4.95 12,380 -11.38 0.0043
2023-08-11 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 73,543 33,439 83.38 13,969 73.88 0.0047
2023-05-12 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 40,104 -7,247 -15.30 8,034 -28.61 0.0029
2023-02-08 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 47,351 1,655 3.62 11,253 23.01 0.0042
2022-11-10 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 45,696 20,629 82.30 9,147 150.12 0.0040
2022-08-10 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 25,067 -2,909 -10.40 3,657 -19.96 0.0015
2022-05-16 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 27,976 -61,497 -68.73 4,569 -69.89 0.0015
2022-02-14 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 89,473 67,281 303.18 15,173 262.12 0.0043
2021-11-15 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 22,192 3,543 19.00 4,190 32.59 0.0013
2021-08-13 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 18,649 -2,573 -12.12 3,160 5.47 0.0010
2021-05-12 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 21,222 82 0.39 2,996 9.06 0.0010
2021-02-11 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 21,140 -756 -3.45 2,747 -13.83 0.0009
2020-11-12 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 21,896 -2,492 -10.22 3,188 -11.74 0.0012
2020-07-31 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 24,388 -17,538 -41.83 3,612 -20.84 0.0015
2020-05-01 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 41,926 9,146 27.90 4,563 20.87 0.0022
2020-02-14 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 32,780 -38,285 -53.87 3,775 -33.93 0.0013
2019-11-14 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 71,065 42,701 150.55 5,714 177.65 0.0022
2019-08-14 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 28,364 -20,270 -41.68 2,058 -54.71 0.0008
2019-05-14 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 48,634 -55,999 -53.52 4,544 -40.43 0.0019
2019-02-14 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 104,633 11,771 12.68 7,628 -6.15 0.0035
2018-11-14 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 92,862 38,830 71.86 8,128 52.70 0.0032
2018-08-14 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 54,032 -43,989 -44.88 5,323 -54.41 0.0023
2018-05-15 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 98,021 18,107 22.66 11,675 14.99 0.0050
2018-02-14 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 79,914 36,548 84.28 10,153 99.27 0.0042
2017-11-14 2017-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 43,366 -22,701 -34.36 5,095 -3.30 0.0024
2017-11-14 2017-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 66,067 4,082 6.59 5,269 65.85 0.0027
2017-08-14 2017-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 66,067 4,082 5,269
2017-11-14 2017-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 61,985 -50,301 -44.80 3,177 -24.43 0.0017
2017-05-12 2017-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 61,985 -50,301 3,177
2017-02-14 2016-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 112,286 48,686 76.55 4,204 -2.46 0.0023
2016-11-14 2016-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 63,600 -32,240 -33.64 4,310 -18.95 0.0026
2016-08-12 2016-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 95,840 54,805 133.56 5,318 106.44 0.0033
2016-05-12 2016-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 41,035 -73,320 -64.12 2,576 -76.07 0.0017
2016-02-16 2015-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 114,355 57,018 99.44 10,765 133.62 0.0070
2015-11-13 2015-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 57,337 24,531 74.78 4,608 17.19 0.0033
2015-08-14 2015-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 32,806 9,470 40.58 3,932 61.41 0.0026
2015-05-14 2015-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 23,336 -11,298 -32.62 2,436 -27.50 0.0017
2015-02-17 2014-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 34,634 34,634 3,360 0.0023
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-05 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM Call 2,988 -66.76 989 -72.36 n/a n/a n/a
2026-01-29 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM Call 8,988 200.80 3,574 162.41 n/a n/a n/a
2025-11-13 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM Call 2,988 -80.71 1,363 -73.03 n/a n/a n/a
2025-08-14 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM Call 15,488 5,050 n/a n/a n/a
2024-08-14 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2024-05-13 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM Call 10,000 28.21 1,494 0.13 n/a n/a n/a
2024-02-09 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM Call 7,800 1,493 n/a n/a n/a
2023-08-11 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2023-05-12 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM Call 2,000 0.00 401 -15.79 n/a n/a n/a
2023-02-08 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM Call 2,000 475 n/a n/a n/a
2019-05-14 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2019-02-14 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM Call 34,700 2,530 n/a n/a n/a
2018-02-14 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2017-11-14 2017-09-30 13F ALNYLAM PHARMACEUTICALS COM Call 71,000 -43.65 8,342 -17.00 n/a n/a n/a
2017-11-14 2017-06-30 13F/A ALNYLAM PHARMACEUTICALS COM Call 126,000 10,050 n/a n/a n/a
2017-08-14 2017-06-30 13F ALNYLAM PHARMACEUTICALS COM Call 126,000 10,050 n/a n/a n/a
2016-02-16 2015-12-31 13F ALNYLAM PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2015-11-13 2015-09-30 13F ALNYLAM PHARMACEUTICALS COM Call 50,800 6,250.00 4,082 4,152.08 n/a n/a n/a
2015-08-14 2015-06-30 13F ALNYLAM PHARMACEUTICALS COM Call 800 -11.11 96 2.13 n/a n/a n/a
2015-05-14 2015-03-31 13F ALNYLAM PHARMACEUTICALS COM Call 900 80.00 94 91.84 n/a n/a n/a
2015-02-17 2014-12-31 13F ALNYLAM PHARMACEUTICALS COM Call 500 49 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-05 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM Put 0 -100.00 0 n/a n/a n/a
2026-01-29 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM Put 10,500 0.00 4,175 -12.80 n/a n/a n/a
2025-11-13 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM Put 10,500 0.00 4,788 39.88 n/a n/a n/a
2025-08-14 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM Put 10,500 3,424 n/a n/a n/a
2024-11-14 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2024-08-14 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM Put 24,900 -9.45 6,051 47.24 n/a n/a n/a
2024-05-13 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM Put 27,500 89.66 4,110 48.07 n/a n/a n/a
2024-02-09 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM Put 14,500 202.08 2,775 226.47 n/a n/a n/a
2023-11-09 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM Put 4,800 850 n/a n/a n/a
2018-02-14 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2017-11-14 2017-09-30 13F ALNYLAM PHARMACEUTICALS COM Put 45,200 5,311 n/a n/a n/a
2015-05-14 2015-03-31 13F ALNYLAM PHARMACEUTICALS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2015-02-17 2014-12-31 13F ALNYLAM PHARMACEUTICALS COM Put 100 10 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.